June 15, 2024

Athens News

News in English from Greece

Experimental cancer drug shows 100% efficacy for the first time

A new experimental drug for the treatment of cancer has shown stunning results. All study participants went into remission, and the number of cancer cells in their bodies decreased to an undetectable level, according to the New England Journal of Medicine.

“This is the first time in the history of cancer treatment that this has happened,” experts comment. Participants were treated for rectal cancer for six months.

The results of the study were published in an article for a scientific journal. New England Journal of Medicine. It says that 12 people underwent experimental treatment, as a result, all participants in the study went into remission without the traditional course of chemotherapy.

“In my opinion, this is the first time this has happened in the history of cancer treatment,” said Luis Diaz Jr., a researcher at the Sloan Kettering Cancer Center (MSK).

It is noted that the study participants underwent a six-month course of immunotherapy in the hope of defeating rectal cancer. At the end of the treatment, the participants learned that they were in remission. One of the patients, who lives in New York, was preparing to undergo scheduled chemotherapy when her oncologist called and said that it was no longer necessary.

“It was incredibly rewarding to see the tears of happiness in the patients in this study when they realized that the treatment was successful,” admits oncologist Andrea Cherchek.

Doctors at the MSK Cancer Center wanted to find out in their study whether immunotherapy alone could treat cancer. But doctors didn’t expect the experimental treatment to work so well. Moreover, none of the 12 participants experienced adverse reactions to Dostarlimab. It allows immune cells in the human body to recognize and attack cancer cells, experts say.

Despite the intriguing results of the study, the new drug is hardly a miracle drug. According to the statistics given

Source link

Verified by MonsterInsights